title: Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation.
abstract: Plasma cell dyscrasias (PCD) are a spectrum of diseases characterized by clonal proliferation of plasma cells secreting a monoclonal immunoglobulin. Although considered an incurable disease, a combination of autologous stem cell transplant with novel therapies, including lenalidomide, has improved the overall and progression-free survival of these patients. Renal impairment is an important complication of the disease that, in some cases, progresses to end-stage renal disease. Due to the characteristics of PCD, traditionally these patients have not been candidates for renal transplantation. However, treatment improvement allows a reconsideration of this perception, especially in younger patients with good performance status and treatment response. We report two cases of patients diagnosed with PCD undergoing renal transplantation after autologous stem cell transplantation, both cases under treatment with lenalidomide. We also report their perioperative management and their outcome.
authors: Department of Hematology and Hemotherapy, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. anasanchezquintana@gmail.com
authors: Ana
authors: A
authors: Sánchez Quintana
authors: Pablo Ríos
authors: PR
authors: Rull
authors: Joaquín Breña
authors: JB
authors: Atienza
authors: Cristina Notario
authors: CN
authors: McDonnell
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000175:diagnosis / Q000209:etiology / Q000601:surgery*; D016030:Kidney Transplantation; D000077269:Lenalidomide; D008297:Male; D010265:Paraproteinemias / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077269:Lenalidomide
keywords: autologous stem cell transplantation; lenalidomide; plasma cell dyscrasias; renal transplantation